Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.

  title={Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.},
  author={David A. Proia and Richard C. Bates},
  journal={Cancer research},
  volume={74 5},
As with many physiologic processes that become subverted during tumorigenesis, the chaperoning activity of heat shock protein 90 (HSP90) is often exploited by cancer cells to confer aberrant proliferative, survival, and/or metastatic potential. Functional inhibition of HSP90 results in the degradation of its client proteins, in turn providing a means to concomitantly disrupt multiple oncogenic signaling cascades through one molecular target. Pharmacologic blockade of HSP90 has, therefore… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-10 of 36 extracted citations


Publications referenced by this paper.
Showing 1-10 of 43 references

Targeted inhibitionof themolecular chaperoneHsp90overcomes ALK inhibitor resistance in non-small cell lung cancer

  • J Sang, J Acquaviva, JC Friedland, DL Smith, M Sequeira, C Zhang
  • Cancer Discov 2013;3:430–43
  • 2013
Highly Influential
5 Excerpts

Heat shock protein 90: inhibitors in clinical trials

  • BiamonteMA, R Van deWater, JW Arndt, RH Scannevin, D Perret, WC. Lee
  • J Med Chem 2010;53:3–17
  • 2010
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…